The release of monoamine neurotransmitters from cell bodies and dendrites has an important role in behavior, but the mechanism (vesicular or nonvesicular) has remained unclear. Because the location of vesicular monoamine transporter 2 (VMAT2) defines the secretory vesicles capable of monoamine release, we have studied its trafficking to assess the potential for monoamine release by exocytosis. In neuroendocrine PC12 cells, VMAT2 localizes exclusively to large dense-core vesicles (LDCVs), and we now show that cytoplasmic signals target VMAT2 directly to LDCVs within the biosynthetic pathway. In neurons, VMAT2 localizes to a population of vesicles that we now find undergo regulated exocytosis in dendrites. Although hippocampal neurons do not express typical LDCV proteins, transfected chromogranins A, B, and brainderived neurotrophic factor (BDNF) colocalize with VMAT2. VMAT2 thus defines a population of secretory vesicles that mediate the activity-dependent somatodendritic release of multiple retrograde signals involved in synaptic function, growth, and plasticity.
Introduction
Unlike most classical neurotransmitters, monoamines undergo release from the cell body and dendrites as well as axon terminals (Geffen et al., 1976; Adell and Artigas, 1998) . Somatodendritic dopamine release in the ventral tegmental area is required for the induction of behavioral sensitization to amphetamine, a model for drug craving that involves the activation of presynaptic D1 dopamine receptors (Vezina, 2004) . In addition, dopamine release in the midbrain activates D2 autoreceptors that may contribute to the role of dopamine in motor control Bergquist et al., 2003) . Somatodendritic serotonin release has also been implicated in the autoregulation of dorsal raphe excitability (Adell and Artigas, 1998) . Somatodendritic release thus contributes to the pathological role of dopamine in drug abuse and presumably to the physiological role of monoamines in normal behavior. However, the mechanism of somatodendritic monoamine release remains unclear.
Somatodendritic dopamine release may involve either regulated exocytosis of vesicles containing transmitter or efflux by a nonvesicular mechanism. Supporting an exocytic mechanism, somatodendritic release produced by electrical stimulation may require Ca 2+ and vesicular storage of dopamine (Rice et al., 1997; Jaffe et al., 1998; Beckstead et al., 2004) . However, amphetamines are known to promote flux reversal mediated by the plasma membrane dopamine transporter (DAT) (Sulzer et al., 1995) , and this may also require Ca 2+ (Gnegy et al., 2004) . Additional work has further suggested that somatodendritic dopamine release is only partially Ca 2+ dependent and insensitive to the clostridial neurotoxins that cleave SNARE proteins required for vesicle fusion (Chen and Rice, 2001; Bergquist et al., 2002) . A recent study has also indicated the sensitivity of activity-dependent somatodendritic release to DAT inhibitors (Falkenburger et al., 2001 ). On the other hand, not all SNARE proteins are sensitive to the clostridial toxins, and inhibition of DAT may also deplete vesicular stores of monoamine (Giros et al., 1996) .
To assess the potential for somatodendritic release of monoamine by exocytosis, we have studied the trafficking of the neuronal vesicular monoamine transporter 2 (VMAT2) because its location defines the vesicles capable of filling with monoamine and hence exocytic release. In contrast to the vesicular GABA and glutamate transporters, which are almost exclusively axonal (Fremeau et al., 2004) , VMAT2 localizes to the cell bodies and dendrites as well as axon terminals of monoamine neurons. In axons, VMAT2 localizes to synaptic vesicles and large dense-core vesicles (LDCVs) (Nirenberg et al., 1995) . In cell bodies and dendrites, the transporter resides on poorly characterized tubulovesicular structures (Nirenberg et al., 1996) , and it has remained unclear whether these membranes undergo regulated exocytosis.
To understand the trafficking of VMAT2, we have used heterologous expression in rat pheochromocytoma PC12 cells. In PC12 cells, VMAT2 localizes exclusively to LDCVs rather than to the synaptic-like microvesicles that these cells also contain (Liu et al., 1994; Weihe et al., 1994) . Less abundant than synaptic vesicles in neurons, LDCVs are the predominant class of secretory vesicle in endocrine cells, contain proteins as well as classical transmitters, and respond to different stimuli than synaptic vesicles. LDCVs also differ from synaptic vesicles in their biogenesis. Synaptic vesicles form locally at the nerve terminal: membrane proteins enter synaptic vesicles only after arrival at the plasma membrane (Regnier-Vigouroux et al., 1991; Takei et al., 1995; Schmidt et al., 1997) . In contrast, LDCVs bud directly from the trans-Golgi network (TGN) to form the regulated (as opposed to constitutive) secretory pathway (Arvan and Castle, 1998) . However, little is known about the mechanisms that sort membrane proteins such as VMAT2 to synaptic vesicles or LDCVs.
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The sorting of proteins to LDCVs has been considered to rely on intralumenal aggregation and lipid interactions (Zhang et al., 2003; Lou et al., 2005) . Indeed, the abundant secreted protein chromogranin A can drive the formation of LDCVs in heterologous cells, apparently by providing a nidus for aggregation in the lumen of the vesicle (Kim et al., 2001) . Nonetheless, the cytoplasmic domains of several proteins including VMAT2 (Milgram et al., 1994; Modderman et al., 1998; Blagoveshchenskaya et al., 1999; Krantz et al., 2000) also promote localization to LDCVs. Targeting to LDCVs may therefore involve a direct interaction with cytosolic sorting machinery, but it has remained unclear whether this interaction influences trafficking directly in the TGN or indirectly by, for example, promoting retrieval to the TGN after constitutive exocytosis.
Previous work has demonstrated that a C-terminal dileucine-like signal mediates the internalization of VMAT2 from the plasma membrane (Tan et al., 1998) . In other membrane proteins, acidic residues 4 and 5 positions upstream of a dileucine signal have been found to be required for internalization (Pond et al., 1995; Dietrich et al., 1997) , and VMAT2 contains highly conserved glutamates at these positions (KEEKMAIL). However, replacement of these residues (Glu-478 and Glu-479) with alanine (mutant EE/AA) does not impair VMAT2 endocytosis (Tan et al., 1998) . Rather, these residues influence other sorting events: the EE/AA mutation reduces steady-state expression on LDCVs , implicating cytosolic rather than lumenal or membrane interactions in sorting to the regulated secretory pathway. On the other hand, the extended dileucine motif might target VMAT2 to LDCVs simply by promoting its retrieval to the TGN after misdelivery to the plasma membrane.
We have now used metabolic labeling and pulsechase analysis to show that the extended dileucine motif sorts VMAT2 directly to LDCVs within the biosynthetic pathway, presumably at the level of the TGN. The same mutations that disrupt sorting to LDCVs in PC12 cells also increase cell-surface delivery in neurons, suggesting that VMAT2 sorts to a regulated secretory pathway in neurons as well. Moreover, we find that VMAT2 undergoes regulated Ca 2+ -dependent exocytosis in dendrites as well as at axon terminals. The EE/AA mutation that disrupts sorting to LDCVs in PC12 cells eliminates the regulated exocytosis of VMAT2 in dendrites but only partially impairs its regulated exocytosis in axons. In addition, we have loaded hippocampal neurons expressing VMAT2 with L-3,4-dihydroxyphenylanine (L-DOPA) and used amperometry to confirm the quantal release of dopamine from cell bodies. Although hippocampal neurons lack typical LDCV markers, transfected chromogranins and brain-derived neurotrophic factor (BDNF) colocalize with VMAT2. Neurons thus express a robust regulated secretory pathway responsible for the dendritic release of multiple retrograde synaptic signals.
Results
The Extended Dileucine-like Motif Targets VMAT2 to LDCVs within the Biosynthetic Pathway If sorting to LDCVs in the TGN were nonselective, VMAT2 would enter nascent constitutive secretory vesicles as well as LDCVs, and selective expression on LDCVs would require multiple rounds of retrieval from the plasma membrane to the TGN. Indeed, LDCV membrane proteins do recycle to the TGN after exocytosis (Hurtley, 1993) . The extended dileucine-like motif might thus indirectly affect localization to LDCVs by promoting the retrieval of VMAT2 from the plasma membrane to the TGN.
To distinguish between direct sorting to LDCVs in the TGN and an indirect pathway involving retrieval from the plasma membrane, we first assessed the rate of cellsurface VMAT2 delivery by taking advantage of an epitope tag (HA) inserted into the large lumenal loop between transmembrane domains 1 and 2 (Tan et al., 1998) . PC12 cells stably expressing wild-type and mutant VMAT2 were incubated with the mouse monoclonal antibody HA.11 for 1 hr at 37ºC and were immunostained with a secondary anti-mouse antibody to detect VMAT2 that had been delivered to the cell surface during that time and with a rat HA antibody to assess total VMAT2 expression. Using this assay, wild-type VMAT2 cannot be detected from the plasma membrane despite high levels of total transporter expression ( Figure 1A ), suggesting direct and efficient entry into LDCVs at the TGN. Alternatively, the wild-type protein might not remain on the plasma membrane long enough to be recognized by the external HA antibody. However, replacement of Glu-478 and -479 upstream of the dileucine-like signal by alanine (EE/AA mutation) results in the detection of substantial VMAT2 at the cell surface ( Figure  1A ). Since wild-type and EE/AA VMAT2 do not differ in the rate of endocytosis (Tan et al., 1998) , the failure to detect wild-type protein at the plasma membrane cannot reflect a difference from the EE/AA mutant in antibody access. Thus, any wild-type VMAT2 delivered to the plasma membrane should also have been detected, demonstrating that the wild-type protein sorts directly to LDCVs and that this process depends on Glu-478 and -479. In addition, the IL/AA mutation affecting Ile-483 and Leu-484 results in high levels of cell-surface VMAT2 ( Figure 1A ), indicating a requirement for the dileucine-like core signal as well as the upstream acidic residues for direct targeting to LDCVs.
We extended the analysis to several other highly conserved residues in VMAT2 that surround Glu-478 and -479 and have no role in endocytosis (Tan et al., 1998) . Alanine replacements of Lys-477 (K/A), and Lys-480 and Met-481 (KM/AA) within the KEEKMAIL motif do not appear to alter the localization of VMAT2 ( Figure  1A ). Like wild-type VMAT2, the K/A and KM/AA mutants exhibit low levels of antibody uptake from the cell surface ( Figure 1A ), suggesting that although highly conserved, Lys-477, Lys-480, and Met-481 are not essential for sorting to LDCVs. However, these antibody feeding experiments assess steady-state delivery of VMAT2 to the plasma membrane rather than the delivery of newly synthesized protein.
We used metabolic labeling to determine whether VMAT2 sorts directly to LDCVs within the biosynthetic pathway. The sulfation of membrane proteins occurs in the TGN (Tooze and Huttner, 1990) , but the level of VMAT2 labeling with 35 S-sulfate was very low even after the insertion of multiple sulfation signals (data not shown). We therefore relied on biosynthetic labeling in the endoplasmic reticulum with 35 S-cysteine and -methionine. Stably transfected cells were labeled for 30 min with 35 S-cysteine/methionine, then incubated in medium containing unlabeled cysteine/methionine for 1, 2, or 3 hr. During the last hour of incubation, anti-HA antibody was added to the medium of half the cells to detect labeled VMAT2 that had arrived at the plasma membrane within that time. Cell-surface and total 35 S-labeled VMAT2 were then immunoprecipitated from the cell extracts, separated by gel electrophoresis, and detected by autoradiography. Using this assay, wild-type VMAT2 is essentially undetectable from the cell surface at all time points tested (<20% total expression at 1-3 hr after labeling) ( Figures 1B and 1C ). This could reflect direct sorting to the regulated secretory pathway, but the possibility again remained that rapid internalization from the plasma membrane might have reduced our ability to detect cell-surface delivery of the newly synthesized wild-type protein. Consistent with this possibility, the internalization-defective IL/AA mutant is easily detected from the plasma membrane ( Figures 1B and 1C) . However, a large proportion of the EE/AA mutant, which is not defective in endocytosis (Tan et al., 1998) , can also be detected at the cell surface within 1 hr after labeling Figure 1 . Wild-Type VMAT2 Sorts Directly to the Regulated Secretory Pathway (A) PC12 cells stably expressing HA-tagged wild-type (wt), K477A (K/A), EE/AA, K480A/M481A (KM/AA), and IL/AA VMAT2 were incubated in medium containing mouse HA.11 antibody for 1 hr at 37ºC, fixed, stained with rat monoclonal HA antibody followed by anti-mouse antibodies conjugated to Cy5 and anti-rat antibodies conjugated to Cy3, and examined by confocal microscopy at the same sensitivity for all constructs. Cells expressing wt, K/A, and KM/AA VMAT2 do not show significant HA antibody labeling relative to total protein expression, suggesting low levels of VMAT2 delivery to the plasma membrane. In contrast, cells expressing EE/AA and IL/AA VMAT2 exhibit high levels of antibody binding, indicating that a substantial proportion of these mutants is delivered to the plasma membrane. (B) Cells were labeled with 0.5 mCi/ml 35 S-cysteine/methionine for 30 min, then incubated for 1, 2, or 3 hr with unlabeled cysteine and methionine. To determine how much 35 S-labeled VMAT2 was delivered to the cell surface during each time interval, HA.11 antibody was added to the medium of half the cells during the last hour of chase. The remaining cells were used to measure total 35 S-labeled VMAT2. Total and cell-surface labeled VMAT2 were then immunoprecipitated and submitted to autoradiography. Total protein (left) and cell-surface protein (right) are shown for wt, EE/AA, and IL/AA VMAT2 at each chase time. Wild-type protein is virtually undetectable at the cell surface at all intervals. In contrast, EE/AA and IL/AA mutants begin to appear at the cell surface within an hour of synthesis and continue to appear there for at least 3 hr. (C) For each VMAT2 construct, the pulse-chase analysis shown in (A) was quantified, and for each interval, cell-surface-labeled VMAT2 was expressed as a fraction of total labeled VMAT2. Error bars represent standard error of the mean, with p < 0.05 for all the comparisons of EE/AA and IL/AA mutants to wild-type at each time interval studied.
( Figures 1B and 1C ). Thus, we should have had no difficulty detecting cell-surface delivery of newly synthesized wild-type VMAT2, and the lack of wild-type VMAT2 at the cell surface indicates that the protein targets directly and selectively to the regulated secretory pathway. Indeed, both IL/AA and EE/AA mutations result in the rapid delivery of VMAT2 to the plasma membrane early after biosynthesis, indicating diversion from regulated to constitutive secretory vesicles. Since the IL/AA mutation affects endocytosis as well as sorting to LDCVs, the EE/AA mutation has a more selective function in targeting to the regulated secretory pathway.
The Extended Dileucine Motif Regulates Cell-Surface Delivery of VMAT2 in Neurons
To determine whether the extended dileucine motif targets VMAT2 to a regulated secretory pathway in neurons, we used heterologous expression in dissociated primary hippocampal culture. In contrast to the small proportion of dopamine neurons in midbrain cultures, hippocampal cultures yield a large number of relatively uniform neurons amenable to transfection. To introduce the VMAT2 cDNA into hippocampal neurons, we used electroporation at the time of plating, which confers modest, uniform expression in a large number of cells. Similar to the endogenous expression by monoamine neurons Nirenberg et al., 1996) , wild-type VMAT2 shows robust somatodendritic expression in transfected hippocampal neurons. Double staining for the synaptic vesicle protein SV2 ( Figure  2B ) confirms the anticipated synaptic localization of VMAT2 in axons, but some of the strongest expression colocalizes with the dendritic protein MAP2 (Figure 2A ). In contrast, vesicular glutamate transporters 1 and 2 remain axonal despite transfection (data not shown). Similar to COS and PC12 cells (Tan et al., 1998) , the IL/AA mutant expressed in neurons shows more cellsurface expression than wild-type VMAT2, on both axons and dendrites ( Figure 2 ). However, the EE/AA mutant shows a punctate distribution indistinguishable from that of wild-type VMAT2 by steady-state immunofluorescence.
We first double stained the transfected neurons for secretogranin 2 to assess localization on LDCVs. However, hippocampal neurons express little if any of this or other granins typically used as markers for LDCVs (data not shown), and most of the secretogranin 2 in hippocampal cultures is glial (Fischer-Colbrie et al., 1993; Calegari et al., 1999) . Because sorting to a regulated secretory pathway reduces constitutive delivery to the cell surface in PC12 cells, we examined the plasmamembrane expression of VMAT2 in neurons by incubating the cultures in HA antibody conjugated directly to the Alexa 488 fluorophore (HA-488). In cells labeled at 37ºC for 2 and 5 min ( Figures 3A and 3B ), wild-type VMAT2 is barely detectable from the cell surface despite high levels of total VMAT2 expression documented by double staining for HA after permeabilization. In contrast, the IL/AA mutant shows robust cell-surface expression. In addition, the EE/AA mutation increases cell-surface expression (Figure 3 ), although not as dramatically as the IL/AA substitution, and quantification of the surface/total fluorescence confirms this result ( Figure 3B ). To analyze the cell-surface expression of VMAT2 biochemically, we used biotinylation of plasmamembrane protein followed by Western analysis. Similar to the immunofluorescence, wild-type VMAT2 shows little cell-surface expression after normalization to total transporter ( Figures 3C and 3D ). The IL/AA mutant shows the most cell-surface expression, and the EE/AA mutant is intermediate.
Since increased cell-surface expression may reflect either an increase in exocytosis or a decrease in endocytosis, we examined the rates of VMAT2 internalization in the transfected hippocampal neurons. The chilled cells were incubated in HA-488 at 4ºC, then warmed for varying times to allow internalization, and the remaining cellsurface fluorophore quenched with an external rabbit antibody to Alexa 488 before permeabilization. Unquenchable HA-488 fluorescence thus reflects internalized VMAT2. Figure 4A illustrates the endocytosis observed after 10 min at 37ºC, and we quantified the surface/total fluorescence using multiple cultures at a range of time points ( Figure 4B ). Wild-type VMAT2 exhibits little cell-surface expression, but the fluorescence that is detected begins to resist quenching after 2 and 5 min of internalization. On the other hand, almost all of the fluorophore bound to the endocytosis-defective IL/AA mutant remains quenchable up to 20 min after the start of internalization ( Figure 4 ). The dramatic difference between unquenched and quenched IL/AA mutant indeed demonstrates the efficiency of quenching. Unlike the IL/AA mutant, the EE/AA mutant begins to internalize around 5 min ( Figure 4 ). Although perhaps slightly delayed, endocytosis of the EE/AA mutant therefore resembles that of the wild-type protein, consistent with previous results in PC12 cells (Tan et al., 1998) . Because the EE/AA mutation increases cell-surface expression without substantially affecting endocytosis, it must increase cell-surface delivery. Although hippocampal neurons contain few LDCVs, at least by staining for the granins (Fischer-Colbrie et al., 1993; Calegari et al., 1999) , the results raise the possibility that the EE/AA mutation diverts VMAT2 from regulated into constitutive secretory vesicles in neurons as well as in PC12 cells.
Regulated Exocytosis of VMAT2 in Dendrites and Axons
To determine whether VMAT2 resides on regulated secretory vesicles in dendrites as well as in axons, we stimulated the transfected cultures by depolarization. In the absence of depolarization, wild-type VMAT2 is barely detectable from the cell surface after incubation for 2 min in Tyrode's medium containing HA-488 ( Figure  5A , upper panels). In Tyrode's medium containing 90 mM KCl and Ca 2+ , however, HA-488 strongly labels synaptophysin + axon terminals and synaptophysin 2 dendrites ( Figure 5A , middle panels). The absence of Ca 2+ eliminates the increase in cell-surface VMAT2 at both sites ( Figure 5A , bottom panels). Quantitation of the surface to total VMAT2 fluorescence in multiple independent experiments confirms that wild-type VMAT2 undergoes regulated, Ca
2+
-dependent exocytosis at cell bodies and dendrites as well as axon terminals ( Figure  5C ). In contrast, the EE/AA mutant shows increased baseline cell-surface expression in axons and dendrites that increases further upon stimulation only in the axons ( Figure 5B ). Quantitation confirms that the EE/AA mutation eliminates regulated exocytosis of the transporter in dendrites but only partially impairs its regulated exocytosis in axons ( Figure 5C ). Thus, the extended dileucine motif is important for regulated somatodendritic exocytosis in neurons.
To confirm that VMAT2 can mediate the release of dopamine at somatodendritic sites, we measured dopamine release directly by amperometric recording. Taking advantage of the heterologous VMAT2 expression, we loaded the transfected hippocampal neurons with catecholamine by incubating them in L-DOPA, the precursor for dopamine. As we showed previously, this compound can undergo conversion to dopamine by endogenous decarboxylases even in cells not normally monoaminergic and confer quantal dopamine release if these cells also express VMAT2 (Pothos et al., 2000) . A GFP fusion to the N terminus of VMAT2 was used to (A) Hippocampal cultures transfected with wt, EE/AA, and IL/AA VMAT2 cDNAs were double stained with a rat antibody to the HA epitope (Aa, Ad, and Ag) and a mouse antibody to MAP2 (Ab, Ae, and Ah), followed by secondary anti-rat antibodies conjugated to FITC and anti-mouse antibodies conjugated to Cy3. Both wt and mutant VMAT2 colocalize with MAP2 in the cell body and dendrites (Ac, Af, and Ai). Unlike the internalization-defective IL/AA mutant, which exhibits high-level expression at the plasma membrane (AgAi), the EE/AA shows a punctate cytoplasmic expression pattern similar to wt VMAT2 (AaAc and Ad-Af). (B) Transfected hippocampal cultures were double stained with rat HA antibody (Ba, Bd, and Bg) and mouse antibody to SV2 (Bb, Be, and Bh), followed by secondary anti-rat antibody conjugated to FITC and anti-mouse antibody conjugated to Cy3. The IL/AA mutant shows increased cell-surface expression (Bg-Bi), but the EE/AA mutant has a punctate localization (Bd-Bf) similar to wt VMAT2 (Ba and Bc). The arrows in (Ba)-(Bf) indicate sites of VMAT2 colocalization with SV2. Scale bar, 10 mm.
guide placement of the 5 mm diameter carbon fiber electrode over transfected cells ( Figure 6A ), which were stimulated by local perfusion with high potassium. Importantly, we recorded over cell bodies rather than dendrites to exclude potential confusion with axonal processes. In addition, cell bodies without adjacent GFP + processes were chosen to exclude contamination by axonal release. Of 54 GFP-labeled transfected cells, 8 displayed quantal release events following stimulation (Figure 6B) , whereas of 36 untransfected (GFP 2 ) cells, none displayed such events, a statistically significant difference (Table 1) . Thus, the amperometry demonstrates that VMAT2 confers the regulated somatodendritic release of dopamine. The frequency of events may seem low, but detection requires placement of the electrode directly over a release site, and even axonal events are detected at low frequency in midbrain culture after depolarization with K + (Staal et al., 2004 ).
The kinetics of transmitter release from transfected hippocampal cell bodies were similar to quantal events measured from small synaptic vesicles at the terminals of cultured dopamine neurons, with a duration at half-maximal amplitude (t1/2) w100 ms (Table 1) (Staal et al., 2004) . In contrast, the LDCVs of chromaffin, mast, and PC12 cells release their contents over tens to hundreds of milliseconds (Travis and Wightman, 1998) . The mean quantal size of neurotransmitter released from hippocampal cell bodies was 2-to 4-fold larger than that recorded from dopamine terminals, but still substantially smaller than release from LDCVs. Thus, the somatic quanta observed here do not resemble release from LDCVs, consistent with the predominant localization of VMAT2 to somatodendritic tubulovesicular membranes that lack a dense core. Nonetheless, the localization of VMAT2 to both LDCVs and somatodendritic secretory vesicles, both of which undergo regulated exocytosis, and the similar effects of the EE/ AA mutation on sorting to both of these vesicle populations, suggest that, despite the absence of a dense core, the VMAT2 + vesicles in neuronal dendrites represent the functional equivalent of LDCVs.
To assess further the relationship between somatodendritic VMAT2
+ vesicles and LDCVs, we cotransfected chromogranin A and B cDNAs into hippocampal neurons (separately) along with that for VMAT2. Double staining showed a very similar distribution of chromogranin A (data not shown) and B with VMAT2 in both cell bodies and processes ( Figures 7A-7C) , supporting the functional similarity of somatodendritic vesicles to LDCVs. What else do the somatodendritic VMAT2 + vesicles release? Considerable previous work has described the regulated release from neurons and in particular from dendrites of neurotrophins such as BDNF (Wetmore et al., 1994; Mowla et al., 1999; Horch and Katz, 2002; Brigadski et al., 2005) . To determine the relationship of VMAT2 + vesicles to those releasing BDNF, we cotransfected the BDNF and VMAT2 cDNAs. Double labeling demonstrates the extensive The IL/AA mutant shows high levels of plasma-membrane expression that remain almost entirely quenchable at 10 min of internalization, indicating the efficiency of the quenching procedure. The EE/AA mutant exhibits intermediate levels of cell-surface expression that resist quenching. Scale bars, 20 mm. (B) Quantitation of the surface/total fluorescence from 160 to 200 puncta of 6 to 12 neurons for each time point of internalization. Despite low levels of cell-surface expression, wt VMAT2 exhibits quenchable fluorescence at 0 and 2 min that becomes resistant to quenching by 5 min. The EE/AA and IL/AA mutants show substantially more labeling than wt VMAT2 (note the difference in scale), but the fluorescence of EE/AA becomes unquenchable by 5 min, whereas that of IL/AA remains quenchable after 20 min of internalization. Error bars represent SEM. Neuroncolocalization of these two proteins ( Figures 7D-7F ). In contrast, the endosomal protein EEA1 implicated in dendritic membrane trafficking exhibits a distribution distinct from VMAT2 ( Figures 7G-7I ), indicating the specificity of VMAT2 for the biosynthetic as opposed to the endocytic pathway in dendrites. In addition, since postsynaptic glutamate receptors undergo regulated membrane trafficking that underlies certain forms of synaptic plasticity, we double stained for the glutamate receptor subunit GluR1 and for the postsynaptic density protein PSD95, which associates with glutamate receptors (Bredt and Nicoll, 2003) . The distribution of both PSD95 and GluR1 appears different from VMAT2 ( Figures 7J-7O ), confirming that wild-type VMAT2 resides on a distinct population of regulated secretory vesicles.
Discussion
The results show that in PC12 cells, wild-type VMAT2 is essentially undetectable from the cell surface, consistent with direct targeting to LDCVs. However, the IL/ AA mutation increases cell-surface delivery of the transporter and impairs its endocytosis, raising the alternative possibility that the dileucine-like signal targets VMAT2 to LDCVs by promoting its retrieval from the plasma membrane to the TGN. We now show that the EE/AA mutation also increases cell-surface delivery of VMAT2 but without affecting endocytosis. Since wildtype and EE/AA VMAT2 internalize at similar rates, the failure to detect wild-type protein on the cell surface demonstrates that it sorts directly to LDCVs without passage through the constitutive secretory pathway to the plasma membrane. The metabolic labeling of newly synthesized protein confirms that the extended dileucine-like motif targets VMAT2 directly to LDCVs within the biosynthetic pathway, presumably at the level of the TGN. In contrast to Ile-483 and Leu-484, which influence multiple trafficking events including endocytosis as well as sorting to LDCVs, Glu-478 and -479 thus have a specific role in targeting VMAT2 to the regulated secretory pathway (Figure 8 ).
The results provide evidence that cytoplasmic sequences target a membrane protein directly to LDCVs within the biosynthetic pathway. As a consequence, they refocus attention on the role of cytosolic sorting machinery in LDCV biogenesis. The dileucine-like core of the trafficking motif in VMAT2 suggests an interaction with the family of adaptor proteins (APs or adaptins), which are known to bind both tyrosine-and dileucinebased motifs (Rapoport et al., 1998; Robinson and Bonifacino, 2001) . Consistent with a possible role in sorting to LDCVs, AP-1, -3, and -4 localize to the TGN (Robinson and Bonifacino, 2001) ; however, the role of upstream acidic residues in recognition by these adaptors remains unclear. The monomeric Golgi-localized, gear-containing, ARF binding proteins (GGAs) require upstream acidic residues for recognition of a dileucine motif in cargo proteins such as the mannose-6-phosphate receptor (Puertollano et al., 2001; Zhu et al., 2001 ). On the other hand, they depend primarily on an acidic residue three positions upstream of the dileucine and thus would be unlikely to recognize the dileucine-like sequence in VMAT2 with acidic residues four and five positions upstream. Sorting to LDCVs may therefore require interaction with other, perhaps unidentified adaptor proteins.
In several proteins, acidic residues upstream of dileucine motifs can influence endocytosis (Dietrich et al., 1994; Pond et al., 1995) . Our results now suggest a potential role for these residues in other trafficking events such as sorting to the regulated secretory pathway. Interestingly, mutations in the residues upstream of a tyrosine-based motif redistribute P-selectin away from (C) Quantitation of surface/total fluorescence at cell bodies and dendrites (upper panel) and at axons (lower panel) for wt and EE/AA VMAT2 without and with depolarization in the presence and absence of Ca
2+
. Total VMAT2 + puncta were first identified in axons and dendrites (excluding puncta that were not in close proximity to the plasma membrane in these confocal sections), and the ratio of cell-surface/total VMAT2 fluorescence was then quantified. 180 to 300 axonal and 160 to 200 somatodendritic puncta from 15 to 20 neurons were analyzed. Bars represent mean of surface/total fluorescence 6 SEM. *p < 0.001. LDCVs in mouse pituitary AtT-20 cells, although not in PC12 cells (Modderman et al., 1998; Blagoveshchenskaya et al., 1999) . A tyrosine-based signal also appears to influence sorting of the protein phogrin to LDCVs (Wasmeier et al., 2005) . However, phogrin contains an additional C-terminal sequence (AEEVNAIL) remarkably similar to the extended dileucine-like motif in VMAT2 (KEEKMAIL), and it will be interesting to determine whether this sequence also controls sorting to LDCVs. Consistent with this possibility, Lys-477, Lys-480, and Met-481 (KEEKMAIL) of VMAT2 do not seem to be important for targeting to the regulated pathway, and these are the same residues divergent between VMAT2 and phogrin.
The extended dileucine motif that promotes trafficking to LDCVs in PC12 cells also influences VMAT2 localization in neurons. Similar to the results in other cells, the IL/AA mutation greatly increases cell-surface expression by reducing the rate of internalization. The EE/AA mutation moderately increases cell-surface expression but has minimal effect on endocytosis. In the absence of a change in endocytosis, the increased cell-surface expression of EE/AA VMAT2 must result from increased cell-surface delivery. Increased constitutive exocytosis of this mutant in neurons, together with its diversion from the regulated to constitutive secretory pathway in PC12 cells, indeed suggest that wild-type VMAT2 also sorts directly to a regulated secretory pathway in neurons (Figure 8 ). However, hippocampal neurons contain very few LDCVs, and in culture they do not stain for typical LDCV markers (Fischer-Colbrie et al., 1993; Calegari et al., 1999) .
To assess the regulated exocytosis of VMAT2 in neurons, we depolarized transfected hippocampal cultures and monitored cell-surface delivery of the wild-type transporter. Depolarization dramatically increases the plasma-membrane expression of wild-type VMAT2, and this increase depends on external Ca 2+ , consistent with vesicular release. Further, VMAT2 undergoes regulated exocytosis at dendrites as well as at axon terminals. VMAT2 thus defines a previously uncharacterized class of secretory vesicles without typical LDCV markers that apparently correspond in function to LDCVs (Figure 8) . Indeed, Glu-478 and -479, the same residues that promote sorting to LDCVs in PC12 cells, also direct VMAT2 to regulated somatodendritic secretory vesicles in neurons. The EE/AA mutation increases constitutive cell-surface delivery of VMAT2 in neurons and abolishes the increase in somatodendritic exocytosis produced by depolarization. In contrast, the EE/AA mutation reduces but does not eliminate regulated exocytosis in axons. The regulated secretory pathway to which VMAT2 localizes in neurons may therefore exist at axon terminals as well as at dendrites (Figure 8 , lower panel), as previously suggested from studies of monoamine neurons (Thureson-Klein, 1983; Nirenberg et al., 1995) . However, localization of EE/AA VMAT2 to synaptic vesicles still enables its regulated exocytosis at axons, whereas the absence of an alternative pathway eliminates regulated exocytosis of the mutant in dendrites (Figure 8) .
Persistent regulated exocytosis of the EE/AA mutant at axon terminals suggests that Glu-478 and -479 are not required for the trafficking of VMAT2 to synaptic vesicles. Consistent with this, EE/AA but not wild-type VMAT2 localizes to a population of light vesicles in PC12 cells . Since synaptic vesicles form at the plasma membrane, the low rate of cellsurface delivery apparently restricts the opportunity for wild-type VMAT2 to enter synaptic vesicles. The IL/AA mutation increases cell-surface expression, but also impairs internalization and thus blocks sorting to synaptic vesicles at a different step. In contrast, the EE/AA mutation increases plasma-membrane delivery without impairing endocytosis or sorting to synaptic vesicles (Figure 8) . Glu-478 and -479 are thus required specifically for trafficking to the regulated secretory pathway (LDCVs in endocrine cells) but not to synaptic vesicles.
To confirm the regulated exocytosis of VMAT2 at cell bodies and dendrites, we took advantage of the heterologous expression in hippocampal neurons to load dopamine into secretory vesicles containing VMAT2 and monitor dopamine release directly by amperometry. Focusing on transfected cell bodies without adjacent GFP + processes to avoid confusion of axonal with dendritic processes, we observed quantal release from a substantial fraction of those recorded. Because the carbon fiber electrode can detect dopamine released only from immediately adjacent sites, this underestimates the true proportion of cell bodies capable of exocytic release. The events appeared 2-to 4-fold larger than synaptic vesicle quanta and much smaller than events associated with conventional LDCVs. However, it is difficult to interpret discrepancies in quantal size because we have relied on loading with exogenous L-DOPA in this heterologous expression system rather the endogenous production of L-DOPA by tyrosine hydroxylase in native monoamine neurons. On the other hand, the quantal events recorded at cell bodies are very brief, much more similar in duration to axonal release from synaptic vesicles than from LDCVs, which are 2 to 3 orders of magnitude longer. Since release from the dense core accounts for the prolonged events observed in chromaffin cells, the brevity of events described here supports the absence of a dense core from most regulated secretory vesicles in neurons. This does not exclude the existence of a small fraction of vesicles with a dense core, as previously observed in midbrain dopamine neurons For isolated GFP + cell bodies, the results indicate the mean of the average values from each recorded cell 6 SEM (n = 8 cells). GFP 2 cells (untransfected) in the same cultures showed no amperometric events. *denotes significant difference from transfected neurons by c 2 analysis, p = 0.16. (Nirenberg et al., 1996) , but the results do suggest that the more abundant vesicles without a dense core can also undergo regulated exocytosis and apparently confer most of the release from this secretory pathway. Recent work has demonstrated the regulated exocytosis of membrane and secreted proteins at dendrites. Long-term potentiation involves the insertion of AMPA-type glutamate receptors into the postsynaptic membrane, but these receptors derive from a pool of recycling endosomes (Bredt and Nicoll, 2003) rather than the biosynthetic pathway. Consistent with this difference, the subcellular distribution of VMAT2 does not resemble that of endosomal protein EEA1, the AMPA receptor subunit GluR1, or the associated PSD95. On the other hand, the secretion of soluble proteins such as growth factors must derive from the biosynthetic pathway, and repeated observations have demonstrated the depolarization-dependent release of neurotrophins Hippocampal neurons were transfected with cDNAs for chromogranin B (CgB) fused to YFP (A-C), or brain-derived neurotrophic factor (BDNF) fused to GFP (D-F), along with the cDNA for HA-tagged wt VMAT2. After 12-18 days in vitro, the cells were double stained for YFP or GFP using a rabbit GFP antibody and a secondary antibody conjugated to FITC, and for HA-tagged VMAT2 using either a mouse or rat primary antibody and corresponding secondary antibodies conjugated to either Cy3 or Cy5. Endogenous endosomal antigen EEA1 (G-I), the postsynaptic density protein PSD95 (J-L), and the glutamate receptor subunit GluR1 (M-O) were labeled using mouse antibodies to EEA1 and PSD95, and a rabbit antibody to GluR1. VMAT2 colocalizes extensively with CgB and BDNF but exhibits a distribution distinct from EEA1, PSD95, and GluR1. The merged image shows HA-VMAT2 in red and the others in green. Scale bar, 20 mm.
from a variety of cell types, including PC12 cells and hippocampal neurons (Edwards et al., 1988; Wetmore et al., 1994; Heymach et al., 1996; Mowla et al., 1999; Balkowiec and Katz, 2002; Brigadski et al., 2005) . In addition, neurotrophins have been found to reside within a distinct population of secretory vesicles that also contain the Ca 2+ -dependent activator proteins for secretion (CAPS1 and 2) required specifically for the exocytosis of LDCVs (Tandon et al., 1998; Sadakata et al., 2004) . We now find that, after cotransfection, VMAT2 indeed colocalizes extensively with BDNF in axons and dendrites, and BDNF, like VMAT2, undergoes exocytosis at axon terminals as well as dendrites (Kohara et al., 2001) . Taken together, the results indicate that VMAT2 and BDNF sort to the same population of regulated secretory vesicles. Finally, we have cotransfected the hippocampal neurons with chromogranins A and B and find that, despite the absence of endogenous chromogranin in hippocampal neurons, the introduced proteins also colocalize extensively with VMAT2. VMAT2 and BDNF thus sort to a population of regulated secretory vesicles that resemble LDCVs in many respects, such as biogenesis and regulated exocytosis, but lack the usual components of a dense core.
In summary, we find that neurons express a regulated secretory pathway much more extensive than previously anticipated from the identification of LDCVs. Specific cytoplasmic signals target the membrane protein VMAT2 directly to this pathway, focusing attention on the role of cytosolic machinery in the biogenesis of these vesicles. Trafficking of VMAT2 to the regulated secretory pathway in neurons also confers the regulated somatodendritic release of monoamine by exocytosis, and manipulating the pathway will allow us to assess the role of somatodendritic release in behavior. Further, colocalization of VMAT2 with BDNF suggests a general role for this regulated secretory pathway in the release of multiple retrograde signals required for activity-dependent synaptic growth and plasticity.
Experimental Procedures Molecular Biology
For expression in neurons, all cDNAs were subcloned under the control of the chicken actin promoter (a generous gift of J.L. Rubenstein). Chromogranin A (CgA)-YFP and B (CgB)-YFP were produced by inserting CgA and CgB cDNAs into the pEYFP-N3 vector (Clontech). BDNF-GFP was a generous gift of B. Lu (NINDS).
PC12 Cell Culture and Immunofluorescence PC12 cell culture, transfection, and immunofluorescence were performed as described . To assess internalization, cells treated with NGF (50 ng/ml) for 2-3 days were incubated for 1 hr at 37ºC with anti-HA mouse monoclonal antibody HA.11 (Covance), washed, fixed, and stained with the anti-HA rat monoclonal antibody 3F10 (Roche), followed by secondary anti-mouse antibodies conjugated to Cy5 and anti-rat antibodies conjugated to Cy3. All fluorescence was detected by confocal laser microscopy.
Pulse-Chase Analysis and Immunoprecipitation PC12 cells were labeled for 30 min at 37ºC in cys-and met-free medium containing 0.5 mCi/ml 35 S-cys/met, washed, and incubated at 37ºC in the same medium for 1-3 hr. To detect 35 S-labeled VMAT2 on the plasma membrane, HA.11 antibody (1:100) was added to the medium of half the cells during the last hour of incubation. The remaining cells were used to measure total 35 S-labeled VMAT2 for each time interval. Cells were harvested in 50 mM Tris (pH 7.5), 150 mM NaCl, 10 mM EDTA, 5 mM EGTA, 1% Triton X-100, 0.2% SDS, 20 mg/ml PMSF, 2 mg/ml pepstatin, 2 mg/ml leupeptin (immunoprecipitation, or IP buffer) and postnuclear supernatants from cells that had been incubated in HA.11 were incubated with protein G-agarose. To detect total VMAT2, the remaining supernatants were incubated with HA.11 prebound to protein G-agarose. After overnight incubation at 4ºC, the protein G-agarose was sedimented, washed, the proteins eluted with SDS sample buffer, separated by electrophoresis through SDS-polyacrylamide, and submitted to autoradiography. The films were optically scanned, quantified using NIH Image, and the amount of ) and hence wt VMAT2 does not have the opportunity to reach the synaptic-like microvesicles (SLMVs) of PC12 cells, which form at the cell surface. In contrast, EE/AA and IL/AA VMAT2 (right) both traffick to constitutive secretory vesicles (CSVs), which undergo spontaneous, unstimulated exocytosis. Constitutive exocytosis allows the EE/AA mutant to enter SLMVs, but the IL/AA mutant has a defect in endocytosis, blocking entry to SLMVs and trapping the protein on the plasma membrane. In neurons (bottom panels), VMAT2 localizes to regulated secretory vesicles (RSVs) functionally similar to LDCVs but without secretogranin + cores. VMAT2 also localizes to synaptic vesicles (SVs), suggesting either that the stimulated exocytosis of RSVs allows access to the plasma membrane and entry to SVs, or that the wild-type protein sorts to CSVs as well as to RSVs in these cells. Since axons (left) contain both SVs and RSVs but dendrites (right) contain only RSVs, the EE/AA mutation that impairs sorting to RSVs but not SVs reduces the regulated VMAT2 exocytosis at axons, and eliminates its regulated exocytosis at dendrites. min, washed in DMEM (Gibco BRL) containing 10% FBS, triturated, resuspended in fresh DMEM/10% FBS, and electroporated with 3 mg DNA per 3-5 3 10 6 cells (Amaxa). After transfection, the cells were plated in complete NB (Neurobasal medium containing 2% B27/ 1% GlutaMAX/penicillin-streptomycin/20 mM HEPES [pH 7.4]) at a density of 100,000 per 12 mm poly-L-lysine-coated coverslip (for immunofluorescence) and 2 3 10 6 per well in a 6-well plate (for biochemical analysis). Cultures were fed by replacing half the media with fresh media every 3-5 days.
Transfected primary hippocampal cultures grown for 12-18 days in vitro were fixed, permeabilized, and blocked in phosphatebuffered saline (PBS) containing 0.02% saponin/1% fish gelatin/ 5% BSA before immunostaining for HA with rat anti-HA 3F10 (Roche) and mouse HA11 (Covance), for MAP2 with mouse HM2 mAb (Sigma), and for SV2 with a mouse mAb (a generous gift of R. Kelly). Monoclonal antibodies to EEA1 (1:50) and PSD-95 were obtained from BD Biosciences and Affinity BioReagents, respectively, and rabbit polyclonal antibodies to GluR1 and GFP from Chemicon and Molecular Probes, respectively. The immune deposits were detected with donkey anti-rabbit antibodies conjugated to FITC, donkey anti-mouse, -rat, or -rabbit antibodies conjugated to Cy3, and/or donkey anti-mouse, -rat, or -rabbit antibodies conjugated to Cy5.
Antibody Uptake by Hippocampal Neurons
Transfected embryonic hippocampal neurons grown 10-12 days in vitro were labeled for 30 min at 4ºC in NB containing 1:100 mouse HA antibody conjugated directly to the Alexa 488 fluorophore (HA-488, Covance), rinsed, and incubated at 37ºC for 0-20 min before internalization was stopped with NB at 4ºC. To identify internalized VMAT2, the remaining cell-surface fluorophore was quenched for 40 min at 4ºC with rabbit anti-Alexa 488 (Molecular Probes) diluted 1:10 in NB. Unquenched control neurons were incubated for the same time without anti-Alexa 488. After washing, the cells were fixed and immunostained with mouse HA.11 as above, followed by donkey anti-mouse antibody conjugated to Cy3. Antibody feeding experiments were performed by incubating the transfected neurons for 2 and 5 min with HA-488 in complete NB/2%FBS at 37ºC before washing in cold NB, fixation, and immunostaining with mouse HA.11 antibody, followed by secondary donkey anti-mouse antibody conjugated to Cy3. The immunofluorescence from multiple cultures transfected at different times was imaged by confocal microscopy, quantified using Zeiss software, and areas drawn to cover the processes of individual transfected neurons used to calculate the ratio of surface-labeled to total VMAT2 fluorescence. Since different antibodies were used to detect the surface and total transporter, the ratio of surface/total fluorescence is arbitrary. One-way ANOVA was used for the statistical analysis.
Cell-Surface Biotinylation
Hippocampal cultures were maintained for 12-13 days after transfection, washed, chilled on ice for 10-20 min, and incubated with gentle agitation for 30 min with freshly prepared 0.5-0.8 mg/ml biotin (Ez-link-sulfo-NHS-SS-Biotin, Pierce) in PBS at 4ºC. The unreacted biotin was quenched with cold 100 mM glycine for 20 min at 4ºC, and the cells lysed in 0.2% Triton X-100/150 mM NaCl/25 mM KCl/ 10 mM Tris (pH 7.4) (lysis buffer) containing protease inhibitors for 30 min at 4ºC. Biotinylated protein was recovered from the postnuclear supernatant by incubation with UltraLink Immobilized NeutrAvidin (50% slurry, Pierce) for 12-16 hr at 4ºC, eluted in SDS sample buffer/200 mM DTT, and immunoblotted with rat HA antibody 3F10 and a monoclonal mouse NMDAR1 antibody (Pharmingen) followed by, respectively, secondary anti-rat and -mouse antibodies conjugated to HRP (Amersham Biosciences) and detection by enhanced chemiluminescence. The emission was captured with a FluorChemÔ Imager (Alpha Innotech), quantified using the FluorChem software, and one-way ANOVA used for statistical analysis of three independent experiments.
Stimulation of Transfected Hippocampal Neurons
Hippocampal neurons transfected as above with VMAT2 cDNAs were rinsed in warm Tyrode's solution (in mM: 119 NaCl, 2.5 KCl, 2 CaCl 2 , 2 MgCl 2 , 30 glucose, 25 HEPES [pH 7.4]) containing 10 mM CNQX to block AMPA receptors and 50 mM APV to block NMDA receptors, and stimulated for 2 and 5 min at 37ºC in either Tyrode's solution containing 90 mM KCl (reducing the NaCl to 31.5 mM), in the same solution without Ca 2+ but with 1 mM EGTA, and in standard Tyrode's solution. Under all conditions, the cells were incubated in the presence of mouse HA-Alexa 488 antibody to label surface HA-tagged VMAT2, washed, fixed, and immunostained with mouse HA.11 antibody for total VMAT2 and rabbit polyclonal antibody for synaptophysin (Zymed), followed by secondary donkey anti-mouse antibody conjugated to Cy3 and donkey anti-rabbit antibody conjugated to Cy5. Areas drawn to cover HA + /synaptophysin + puncta (representing axonal terminals) and HA + /synaptophysin 2 puncta (somatodendritic sites) of individual neurons from multiple cultures were used to calculate the ratio of surface-labeled versus total fluorescence for wild-type and EE/AA VMAT2. Puncta not near the cell surface were excluded from the analysis because we could not have detected the exocytosis of these membranes. One-way ANOVA was used for the statistical analysis.
Amperometric Recordings
Hippocampal neurons were cultured as previously described from postnatal rats (Pothos et al., 1998) , plated directly onto laminincoated coverslips, maintained in vitro for 1 week before transfection with Effectene (Qiagen), and amperometric recordings performed 1 week after transfection as previously described (Staal et al., 2004) . The cultures were treated with 100 mM L-DOPA for at least 1 hr before recording, and the amperometry was performed in recording solution (in mM: 130 NaCl, 2 KCl, 10 HEPES, 1 Na 2 HPO 4 , 2 MgCl 2 , 1.2 CaCl 2 , w300 mOsm [pH 7.4]) that also contained 100 mM L-DOPA. Neurons were stimulated with a solution in which 40 mM KCl was substituted for an equivalent concentration of NaCl by local perfusion through a glass micropipette (Picospritzer, General Valve, Fairfield, NJ) for 10 s at 10 psi w30 mm from the recording site. To detect peaks, the raw amperometric data were collected and analyzed using a locally written routine in IGOR Pro (Lake Oswego, OR) available at http://cumc.columbia.edu/dept/neurology/sulzer/ download.html. The comparison between groups was performed by c 2 analysis.
